Doroana M
Baseline susceptibility of primary HIV-2 to entry inhibitors.
- Autores: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
- Ano de Publicação: 2012
- Journal: Antiviral Therapy
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors
BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Ler mais
Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
- Autores: Antunes F, Barroso H, Borrego P, Doroana M, Família C, Maltez F, Marcelino JM, Nilsson C, Quintas A, Taveira N
- Ano de Publicação: 2012
- Journal: Aids
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Resistance+to+antibody+neutralization+in+HIV-2+infection+occurs+in+late+stage+disease+and+is+associated+with+X4+tropism
OBJECTIVES:
To characterize the nature and dynamics of the neutralizing antibody (NAb) response and escape in chronically HIV-2 infected patients.
Ler mais
Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving com- bination therapy including tenofovir
- Autores: Abecasis AB, Abreu R, Aguas MJ, Aldir I, Aleixo MJ, Amaro G, Antunes F, Borges F, Botas J, Branco T, Caixas U, Camacho RJ, Diniz A, Doroana M, Duque L, Faria D, Faria N, Faria T, Fonseca P, Germano I, Gomes F, Guerreiro C, Jesus MB, Mansinho K, Mineiro A, Miranda AC, Narciso J, Neves I, Nina J, Pinheiro S, Pinto IV, Proença P, Reis AP, Roxo F, Sá J, Santos C, Snoeck J, Tavares L, Teófilo E, Theys K, Valadas E, Vandamme AM, Ventura F, Vera J, Vercauteren J
- Ano de Publicação: 2013
- Journal: Journal of Antimicrobial Chemotherapy
- Link: http://www.ncbi.nlm.nih.gov/pubmed/23027713
The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines discouraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the impact of currently recommended regimens on the population selection rate of K65R is presently lacking.
Ler mais
